869885-60-9

Usage

Uses

Used in Pharmaceutical Industry:
Benzofuran-5-ylmethanesulfonyl chloride is used as a reagent for the synthesis of various pharmaceutical compounds. Its ability to introduce the sulfonyl group into organic molecules makes it a valuable tool in the development of new drugs with diverse therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, benzofuran-5-ylmethanesulfonyl chloride is used as a reagent for the synthesis of agrochemicals. The sulfonyl group introduced by Benzofuran-5-ylmethanesulfonyl chloride can enhance the biological activity and effectiveness of agrochemicals, contributing to improved crop protection and yield.
Used in Synthesis of Sulfonamides:
Benzofuran-5-ylmethanesulfonyl chloride is used as a key intermediate in the synthesis of sulfonamides, a class of compounds with diverse biological activities. Sulfonamides have applications in various fields, including medicine, as antimicrobial agents, and in the synthesis of other bioactive compounds.
Safety Precautions:
Due to its high reactivity, benzofuran-5-ylmethanesulfonyl chloride should be handled with caution. It can cause skin and eye irritation, and appropriate safety measures, such as wearing protective clothing and using eye protection, should be taken during its use in laboratory settings or industrial applications.

Upstream product

• 115010-11-2 2,3-dihydrobenzofuran-5-sulfonyl chloride 
• 23145-07-5 5-bromobenzofuran 
• 496-16-2 2.3-dihydrobenzofuran 

Downstream Products

• 1184869-35-9 (S)-2-(benzofuran-5-sulfonamido)-3-(4-((1,3-dimethyl-1H-pyrazol-5-yl)methoxy)phenyl)-N,N-diisobutylpropanamide 
• 1007876-69-8 C₂₈H₃₈N₂O₆S 
• 1007875-94-6 C₂₇H₃₆N₂O₆S 
• 1007877-56-6 C₂₃H₃₀N₂O₄S 
• 1007875-70-8 C₂₇H₃₆N₂O₆S 
• 1007877-55-5 C₂₃H₃₀N₂O₄S 
• 1007877-54-4 C₂₃H₂₈N₂O₄S 
• 1007877-53-3 C₂₂H₂₈N₂O₄S 
• 1160051-78-4 C₃₇H₃₈N₂O₆S 
• 1007876-78-9 C₃₂H₄₁N₃O₇S₂ 
• 1007876-49-4 C₂₆H₃₄N₂O₅S 
• 1007875-27-5 C₂₇H₃₆N₂O₅S 
• 1007875-64-0 C₂₇H₃₆N₂O₆S 

Relevant academic research and scientific papers

Piperazine adenosine monophosphate activated protein kinase (AMPK) agonist and medical application thereof

The invention discloses a piperazine compound with AMPK agonist activity, and a preparation method and medical application of the piperazine compound. The piperazine compound is a compound shown as aformula (I) (please see the specifications for the formula), and a pharmaceutically acceptable salt or ester or a prodrug or N-oxide or solvate thereof. The compound can be used for preparing drugs for preventing or treating AMPK-mediated diseases.

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

BENZOFURAN DERIVED HIV PROTEASE INHIBITORS

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.